Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Coherus Oncology Inc (CHRS)

Coherus Oncology Inc (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 88,306
  • Shares Outstanding, K 115,933
  • Annual Sales, $ 266,960 K
  • Annual Income, $ 28,510 K
  • EBIT $ -115 M
  • EBITDA $ -109 M
  • 60-Month Beta 0.88
  • Price/Sales 0.34
  • Price/Cash Flow 2.71
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.14
  • Most Recent Earnings $-0.35 on 05/12/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 433.63% ( +235.39%)
  • Historical Volatility 83.65%
  • IV Percentile 99%
  • IV Rank 86.97%
  • IV High 497.69% on 04/21/25
  • IV Low 6.15% on 08/15/24
  • Put/Call Vol Ratio 0.29
  • Today's Volume 45
  • Volume Avg (30-Day) 143
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 11,038
  • Open Int (30-Day) 10,789

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.25
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7100 +7.28%
on 05/15/25
0.9000 -15.37%
on 06/09/25
-0.0634 (-7.68%)
since 05/13/25
3-Month
0.7100 +7.28%
on 05/15/25
1.1600 -34.34%
on 04/23/25
-0.1289 (-14.47%)
since 03/13/25
52-Week
0.6603 +15.36%
on 11/05/24
2.4300 -68.65%
on 12/03/24
-1.0183 (-57.21%)
since 06/13/24

Most Recent Stories

More News
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

CHRS : 0.7617 (-3.63%)
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

CHRS : 0.7617 (-3.63%)
Coherus BioSciences: Q1 Earnings Snapshot

Coherus BioSciences: Q1 Earnings Snapshot

CHRS : 0.7617 (-3.63%)
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

CHRS : 0.7617 (-3.63%)
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

CHRS : 0.7617 (-3.63%)
Coherus to Participate in Upcoming Investor Conferences

CHRS : 0.7617 (-3.63%)
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

CHRS : 0.7617 (-3.63%)
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

CHRS : 0.7617 (-3.63%)
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

CHRS : 0.7617 (-3.63%)
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

CHRS : 0.7617 (-3.63%)

Business Summary

Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 0.8009
2nd Resistance Point 0.7905
1st Resistance Point 0.7761
Last Price 0.7617
1st Support Level 0.7513
2nd Support Level 0.7409
3rd Support Level 0.7265

See More

52-Week High 2.4300
Fibonacci 61.8% 1.7540
Fibonacci 50% 1.5452
Fibonacci 38.2% 1.3363
Last Price 0.7617
52-Week Low 0.6603

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar